High Efficacy of the Combination HCV Regimen Grazoprevir and Elbasvir for 8 or 12 weeks with or without Ribavirin in Treatment-NaÏve, Non-Cirrhotic HCV GT1b Infected Patients: an Integrated Analysis

Conference Reports for NATAP

(APASL) 25th Conference of the Asian Pacific
Association for the Study of the Liver
Feb 20-24 2016, Tokyo, Japan


High Efficacy of the Combination HCV Regimen Grazoprevir and Elbasvir for 8 or 12 weeks with or without Ribavirin in Treatment-NaÏve, Non-Cirrhotic HCV GT1b Infected Patients: an Integrated Analysis

	Reported by Jules Levin APASL Tokyo, 2016 Feb 20-14